Independent Data Monitoring Committee recommends early stopping of Phase 3 study of Ibrutinib in relapsed/refractory CLL/SLL patients
8 January 2014 | By Johnson & Johnson
Janssen announced the early stopping of PCYC-1112-CA based on the recommendation of an Independent Data Monitoring Committee, which concluded that the study showed a significant difference in progression-free survival...